Our unique optimally engineered approach leverages an innovative proprietary platform to optimize the function of natural killer cells, thus maximizing cancer cell killing. We also focus on engineering strategies to enhance tumor homing and persistence in-vivo, and overcome exhaustion in the tumor microenvironment.
We are interested in working with leading academic centres, clinical institutions and industry partners to advance scientific understanding, preclinical and clinical evaluation, cell engineering and manufacturing capabilities to drive innovations in the field of NK cell therapies.
- ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies and FLEX-NK™ Bispecific Antibodies 6 December 2023
- European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies 27 June 2023
ONK Therapeutics featured in the Spring Edition of Nature BioPharma Dealmaker
Maximizing synergy and mitigating resistance: novel dual-targeted natural killer cell therapies for cancer